Novartis Deal Sealed, Vanda Plays Up Injectable Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.
You may also be interested in...
J&J Pushes New Treatment Paradigm for Invega Sustenna
Johnson & Johnson is looking at innovative ways to build the value of its just-approved, monthly injectable schizophrenia drug Invega Sustenna, including continuing ongoing outcomes studies and creating appropriate partnerships with payers and others, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia
J&J Pushes New Treatment Paradigm for Invega Sustenna
Johnson & Johnson is looking at innovative ways to build the value of its just-approved, monthly injectable schizophrenia drug Invega Sustenna, including continuing ongoing outcomes studies and creating appropriate partnerships with payers and others, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia
Dealmaking When Pharma's the Only Game in Town
With no public market to provide competition, the theory among biotech's optimists was that Big Pharma would step in and buy lots of bargains. But cheap prices and easy availability haven't increased drug company appetites: They will only buy what they really want. Deal volumes, both for M&A and alliances, are falling, while Big Pharma has learned to put more of the risk back on biotech. What will change this dynamic, putting more bargaining into biotech hands, is the revival of the public market - and there are hints that such a revival may be on the way.